Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment.

ABSTRACT:

Introduction

Nivolumab is a promising treatment in patients with advanced malignancies. Among immune-related adverse events, autoimmune thyroid disorders are frequently reported.

Patient

A 61-year-old male patient had no history of familial or personal thyroid disease. In 2012, this patient, a heavy smoker, presented with non-small-cell lung cancer that was treated with radiotherapy and chemotherapy. In 2015, the cancer progressed with cervical compressive symptoms, and the patient was treated with nivolumab.

Results

After 3 infusions, bilateral eyelid ptosis and bilateral conjunctival redness with chemosis were observed. Ophthalmologic examination revealed severe proptosis with complete ophthalmoplegia but with normal vision, color test, and optic disk. Thyroid funct

SUBMITTER: Campredon P 

PROVIDER: S-EPMC5869363 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature